Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 8/20 | 0.42 |
| ▸ | PGR | P06401 | 7/20 | 0.42 |
| ▸ | NR3C1 | P04150 | 6/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.33 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ACLY | P53396 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20137986 | 0.83 | BRD4 (0.31) | TRPV1 | |
| SCHEMBL4262107 | 0.74 | NR3C2 (0.51) | NR3C2PGRNR3C1PKMMAPK1 | |
| SCHEMBL4265400 | 0.72 | NR3C2 (0.53) | NR3C2PGRNR3C1ADRB2ADRB1 | |
| SCHEMBL18305164 | 0.71 | PGR (0.47) | NR3C2PGRNR3C1PKMMAPK1 | |
| SCHEMBL13343850 | 0.70 | BRD4 (0.54) | NR3C2PGRNR3C1ADRB2ADRB1 | |
| SCHEMBL18305051 | 0.67 | CYP11B1 (0.60) | NR3C2PGRNR3C1 | |
| SCHEMBL16394073 | 0.65 | ATM (0.40) | ALDH1A1 | |
| SCHEMBL16094885 | 0.64 | F2 (0.48) | ALDH1A1POLB | |
| SCHEMBL18305166 | 0.64 | NR3C2 (0.45) | NR3C2PGRNR3C1PKMAR | |
| SCHEMBL4272395 | 0.64 | PGR (0.49) | NR3C2PGRNR3C1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10287299-B2 | Substituted benzo[b][1,4]oxazines and pyrido[3,2-b][1,4]oxazines as modulators of tumor necrosis factor activity | UCB BIOPHARMA SPRL (BE) | 2019-05-14 | — | — | US | disclosed |
| US-20180134728-A1 | Benzoxazinone Derivatives and Analogues Thereof as Modulators of TNF Activity | UCB S.A. (BE) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134728-A1 | Benzoxazinone Derivatives and Analogues Thereof as Modulators of TNF Activity | TNF, NFKBIA, TNFRSF1A | NR3C2 2504/4885PGR 3192/4885NR3C1 1540/4885 |
| US-10287299-B2 | Substituted benzo[b][1,4]oxazines and pyrido[3,2-b][1,4]oxazines as modulators of tumor necrosis factor activity | TNF, TNFRSF1A, NFKBIA | NR3C2 1895/4885PGR 2723/4885NR3C1 668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.